

ASX Announcement

Recce Pharmaceuticals Appoints Dr John Prendergast as Executive Chairman

SYDNEY Australia, 5 September 2022: Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (the **Company**), the Company developing a New Class of Synthetic Anti-infectives, is pleased to announce appointment of Dr John Prendergast as Executive Chairman effective immediately.

US-based Dr Prendergast transitions to the role having joined the Board of Directors as Non-Executive Director in April 2018 and then becoming Non-Executive Chairman in July 2019. As Executive Chairman, he will be working alongside CEO James Graham at an important and exciting time as the Company's anti-infective programs advance locally and internationally.

Dr. Prendergast's comes to the role having experience in commercialising pharmaceuticals for global markets, most notably in the USA, together with an initial background in microbiology. He also serves as Non-Executive Chairman and Co-Founder of Palatin Technologies (NYSE: PTN) developing targeted therapeutics for the treatment of diseases with significant unmet medical need and is Lead Director of Nighthawk Biosciences, Inc. (NYSE: NHWK), a publicly traded, clinical stage immunomodulatory company. Dr. Prendergast has been involved in the development and approval of three (3) New Drug Applications.

Recce Pharmaceuticals Chief Executive Officer James Graham said, "We are delighted to welcome Dr Prendergast to a more active role active in the operational team. Bringing a depth of knowledge and well recognised capability as a veteran in biotechnology and international capital markets, we greatly look forward to his continued contributions over the time ahead."

Dr Prendergast said, "I am delighted to work alongside the expertise I've witnessed among the Recce team over these last 4 years. We are excited about the data from our current clinical programs and have great aspirations as we advance for our future Phase I & Phase



ASX: RCE, FSE: R9Q

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 T +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

II clinical trials as well as a suite of pre-clinical programs for a range of indications. Together with the support of our clinical collaborators, business partners and shareholders, we are proudly building a company with real global impact positioned to address and deliver on one of the greatest unmet medical needs currently faced by humanity.”

Pursuant to his Executive Services Agreement, which replaces his previous letter of engagement, Dr Prendergast will receive remuneration of US\$250,000 per annum, plus superannuation. In addition, the Company may award performance-based bonuses, taking into account such key performance indicators as the Company may set from time to time. The Executive Services Agreement may be terminated by either party without reason on 3 months’ written notice. In the event the Company terminates the Executive Services Agreement, at the end of the 3 month notice period it will also make a payment of 3 months’ salary to Dr Prendergast.

This announcement has been approved for release by Recce Pharmaceuticals Board.



Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

recce.com.au
ACN 124 849 065

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.



Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

recce.com.au
ACN 124 849 065